240 related articles for article (PubMed ID: 32564293)
1. Clinicians versus patients subjective adverse events assessment: based on patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).
Liu L; Suo T; Shen Y; Geng C; Song Z; Liu F; Wang J; Xie Y; Zhang Y; Tang T; Zhang L; Wang W
Qual Life Res; 2020 Nov; 29(11):3009-3015. PubMed ID: 32564293
[TBL] [Abstract][Full Text] [Related]
2. Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library.
Shepshelovich D; McDonald K; Spreafico A; Razak ARA; Bedard PL; Siu LL; Minasian L; Hansen AR
Oncologist; 2019 Apr; 24(4):e146-e148. PubMed ID: 30728278
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial.
Dueck AC; Scher HI; Bennett AV; Mazza GL; Thanarajasingam G; Schwab G; Weitzman AL; Rogak LJ; Basch E
JAMA Oncol; 2020 Feb; 6(2):e193332. PubMed ID: 31556911
[TBL] [Abstract][Full Text] [Related]
4. Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research.
McFatrich M; Brondon J; Lucas NR; Hinds PS; Maurer SH; Mack JW; Freyer DR; Jacobs SS; Baker JN; Mowbray C; Wang M; Castellino SM; Barz Leahy A; Reeve BB
Cancer; 2020 Jan; 126(1):140-147. PubMed ID: 31553494
[TBL] [Abstract][Full Text] [Related]
5. Reliability and Validity of the Korean Language Version of the U.S. National Cancer Institute's Patient-Reported Outcomes Common Terminology Criteria for Adverse Events.
Yoon J; Sim SH; Kang D; Han G; Kim Y; Ahn J; Oh D; Lee ES; Kong SY; Cho J; Mitchell SA
J Pain Symptom Manage; 2020 May; 59(5):1082-1088.e6. PubMed ID: 32044423
[TBL] [Abstract][Full Text] [Related]
6. Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials.
Veitch ZW; Shepshelovich D; Gallagher C; Wang L; Abdul Razak AR; Spreafico A; Bedard PL; Siu LL; Minasian L; Hansen AR
J Natl Cancer Inst; 2021 Aug; 113(8):980-988. PubMed ID: 33616650
[TBL] [Abstract][Full Text] [Related]
7. Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study.
Yeung AR; Pugh SL; Klopp AH; Gil KM; Wenzel L; Westin SN; Gaffney DK; Small W; Thompson S; Doncals DE; Cantuaria GHC; Yaremko BP; Chang A; Kundapur V; Mohan DS; Haas ML; Kim YB; Ferguson CL; Deshmukh S; Bruner DW; Kachnic LA
J Clin Oncol; 2020 May; 38(15):1685-1692. PubMed ID: 32073955
[TBL] [Abstract][Full Text] [Related]
8. Self-evaluation of Adjuvant Chemotherapy-Related Adverse Effects by Patients With Breast Cancer.
Montemurro F; Mittica G; Cagnazzo C; Longo V; Berchialla P; Solinas G; Culotta P; Martinello R; Foresto M; Gallizioli S; Calori A; Grasso B; Volpone C; Bertola G; Parola G; Tealdi G; Giuliano PL; Aglietta M; Ballari AM
JAMA Oncol; 2016 Apr; 2(4):445-52. PubMed ID: 26720497
[TBL] [Abstract][Full Text] [Related]
9. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study.
Basch E; Iasonos A; McDonough T; Barz A; Culkin A; Kris MG; Scher HI; Schrag D
Lancet Oncol; 2006 Nov; 7(11):903-9. PubMed ID: 17081915
[TBL] [Abstract][Full Text] [Related]
10. Integrating the patient voice with clinician reports to identify a hepatocellular carcinoma-specific subset of treatment-related symptomatic adverse events.
Speck RM; Lenderking WR; Shaw JW
J Patient Rep Outcomes; 2017; 2():35. PubMed ID: 30175317
[TBL] [Abstract][Full Text] [Related]
11. Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Chung AE; Shoenbill K; Mitchell SA; Dueck AC; Schrag D; Bruner DW; Minasian LM; St Germain D; O'Mara AM; Baumgartner P; Rogak LJ; Abernethy AP; Griffin AC; Basch EM
J Am Med Inform Assoc; 2019 Apr; 26(4):276-285. PubMed ID: 30840079
[TBL] [Abstract][Full Text] [Related]
12. Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study.
Galizia D; Milani A; Geuna E; Martinello R; Cagnazzo C; Foresto M; Longo V; Berchialla P; Solinas G; Calori A; Grasso B; Volpone C; Bertola G; Parola G; Tealdi G; Giuliano PL; Ballari AM; Aglietta M; Montemurro F
Cancer Med; 2018 Sep; 7(9):4339-4344. PubMed ID: 30030895
[TBL] [Abstract][Full Text] [Related]
13. The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review.
Atkinson TM; Ryan SJ; Bennett AV; Stover AM; Saracino RM; Rogak LJ; Jewell ST; Matsoukas K; Li Y; Basch E
Support Care Cancer; 2016 Aug; 24(8):3669-76. PubMed ID: 27260018
[TBL] [Abstract][Full Text] [Related]
14. Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative.
Reeve BB; McFatrich M; Pinheiro LC; Weaver MS; Sung L; Withycombe JS; Baker JN; Mack JW; Waldron MK; Gibson D; Tomlinson D; Freyer DR; Mowbray C; Jacobs S; Palma D; Martens CE; Gold SH; Jackson KD; Hinds PS
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27650708
[TBL] [Abstract][Full Text] [Related]
15. Validity and reliability of the simplified Chinese patient-reported outcomes version of the common terminology criteria for adverse events.
Yang SS; Chen L; Liu Y; Lu HJ; Huang BJ; Lin AH; Sun Y; Ma J; Xie FY; Mao YP
BMC Cancer; 2021 Jul; 21(1):860. PubMed ID: 34315423
[TBL] [Abstract][Full Text] [Related]
16. Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient's self-reported questionnaire.
Cirillo M; Venturini M; Ciccarelli L; Coati F; Bortolami O; Verlato G
Ann Oncol; 2009 Dec; 20(12):1929-35. PubMed ID: 19622510
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.
Mendoza TR; Dueck AC; Bennett AV; Mitchell SA; Reeve BB; Atkinson TM; Li Y; Castro KM; Denicoff A; Rogak LJ; Piekarz RL; Cleeland CS; Sloan JA; Schrag D; Basch E
Clin Trials; 2017 Jun; 14(3):255-263. PubMed ID: 28545337
[TBL] [Abstract][Full Text] [Related]
18. Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Kluetz PG; Chingos DT; Basch EM; Mitchell SA
Am Soc Clin Oncol Educ Book; 2016; 35():67-73. PubMed ID: 27249687
[TBL] [Abstract][Full Text] [Related]
19. Acceptability of Routine Evaluations Using Patient-Reported Outcomes of Common Terminology Criteria for Adverse Events and Other Patient-Reported Symptom Outcome Tools in Cancer Outpatients: Princess Margaret Cancer Centre Experience.
Albaba H; Barnes TA; Veitch Z; Brown MC; Shakik S; Su S; Naik H; Wang T; Liang M; Perez-Cosio A; Eng L; Mittmann N; Xu W; Howell D; Liu G
Oncologist; 2019 Nov; 24(11):e1219-e1227. PubMed ID: 31409744
[TBL] [Abstract][Full Text] [Related]
20. Use of the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to assess treatment tolerability in pulmonary arterial hypertension: qualitative patient research findings in current and former users of oral selexipag.
Davis S; Edwards T; Norcross L; Fehnel S; Beaudet A; Eckart M; Fastenau J
J Patient Rep Outcomes; 2023 Dec; 7(1):134. PubMed ID: 38108945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
